Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-positive Breast Cancer × Metformin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 119 Breast Neoplasms 34 Prostatic Neoplasms 29 Insulin Resistance 27 Obesity 18 Endometrial Neoplasms 13 Pancreatic Neoplasms 12 Neoplasms 12 Infertility 12 Colorectal Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Anovulation 10 Lung Neoplasms 8 Neoplasm Metastasis 7 Metabolic Syndrome 7 Hyperandrogenism 7 Glioblastoma 7 Squamous Cell Carcinoma of Head and Neck 6 Melanoma 6 Lymphoma, Large B-Cell, Diffuse 5 Diabetes Mellitus 5 Adenocarcinoma 5 Weight Loss 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 4 Mouth Neoplasms 4 Head and Neck Neoplasms 4 Brain Neoplasms 4 Adenocarcinoma of Lung 4 Urinary Bladder Neoplasms 3

Interventions

Trastuzumab 26 pertuzumab 13 Docetaxel 13 pyrotinib 11 Paclitaxel 7 Capecitabine 5 Carboplatin 4 tucatinib 3 Ado-Trastuzumab Emtansine 3 atezolizumab 2 Protons 2 Fulvestrant 2 trastuzumab deruxtecan 1 pegfilgrastim 1 palbociclib 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fluorodeoxyglucose F18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03238495 2021-12-07

HERMET

University of Kansas Medical Center

Phase 2 Unknown

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡